Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma and related lymphomas.
In January 2017, Daiichi Sankyo received exclusive development, manufacturing and commercialization rights for axicabtagene ciloleucel in Japan from California-based Kite, a Gilead Company.
The Japan NDA submission is based on previous pivotal trial data conducted globally by Kite for axicabtagene ciloleucel in addition to results from a phase 2 bridging study conducted by Daiichi Sankyo in Japan. Both trials included patients with four aggressive types of relapsed/refractory B-cell lymphomas including diffuse large B cell lymphoma (DLBCL); primary mediastinal B-cell lymphoma (PMBCL); transformed follicular lymphoma (TFL); and high-grade B cell lymphoma. The Japanese trial met its primary endpoint for objective response rate, and data will be presented at an upcoming medical meeting.
"We are pleased to confirm submission of the NDA for axicabtagene ciloleucel following positive topline results from the phase 2 bridging study in Japan,” said Wataru Takasaki, PhD, Corporate Officer, Head of Oncology Function and Head of R&D Division in Japan, Daiichi Sankyo. “We will continue to work with regulatory authorities to develop this important new cell therapy for eligible patients in Japan who need additional treatment options for relapsed or refractory DLBCL and related lymphomas.”
About Axicabtagene Ciloleucel
Axicabtagene ciloleucel is a CAR T cell therapy directed against CD19 (a cell membrane protein), which harnesses a patient’s own immune system to fight B-cell lymphoma. Axicabtagene ciloleucel received Orphan Drug Designation from the Japan Ministry of Health, Labour and Welfare (MHLW) in 2018 for the treatment of DLBCL, PMBCL, TFL and high-grade B-cell lymphoma.
Axicabtagene ciloleucel is approved in the U.S. and Europe for patients with certain types of relapsed or refractory B-cell lymphoma based on the results of the pivotal ZUMA-1 study.
Unmet Treatment Need in NHL/B-Cell Lymphoma
There were an estimated 509,000 new cases and about 248,000 deaths globally from non-Hodgkin lymphoma (NHL) in 2018.1 In Japan, there were nearly 21,000 new cases of NHL reported in 2012.2
About 85 percent of NHLs are B-cell lymphomas. DLBCL is the most commonly diagnosed NHL, representing about one in five cases.3 Treatment advances have led to improved outcomes for patients with certain types of NHL, but relapsed or refractory disease has remained a significant treatment challenge.4 DLBCL is considered an aggressive form of the disease; however, the majority of DLBCL patients do achieve complete and sustained remission on initial treatment (chemotherapy plus targeted therapy).5 Approximately 40 percent of patients experience relapse or resistance and may subsequently receive additional chemotherapy and/or stem cell transplant (ASCT) if eligible; those who are ineligible for ASCT or who relapse after transplantation have a poor prognosis.5
New and novel treatments such as CAR T cell therapies are providing additional options for some patients with relapsed/refractory DLBCL after two or more lines of treatments have been tried.6
About the Japan Phase 2 Study
The phase 2 multicenter, open-label, single-arm study was planned to evaluate efficacy and safety of axicabtagene ciloleucel in Japanese patients with several aggressive types of large B-cell lymphoma that is refractory or relapsed following one or more lines of standard treatment including drug therapy or stem cell transplant (ASCT). The study enrolled patients with DLBCL, PMBCL, TFL and high-grade B cell lymphoma.
The primary efficacy endpoint is investigator-assessed objective response rate (ORR). Secondary efficacy endpoints include centrally evaluated ORR, duration of response, progression-free survival and overall survival. The study will also measure safety and pharmacokinetics. Enrollment has completed and the study is ongoing at several institutions in Japan. For more information, visit ClinicalTrials.jp.
About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit www.daiichisankyo.com.
1 Bray F. et al. GLOBOCAN 2018. CA CANCER J CLIN 2018;68:394–424.
2 Ferlay J. et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide; IARC No. 11. 2013
3 Lymphoma Research Foundation. About Lymphoma. 2020. Accessed Feb 12, 2020
4 Chao M. Cancer Manag Res. 2013;5:251-269.
5 Skrabek P. et al. Curr Oncol
. 2019 Aug; 26(4): 253–265.
6 American Cancer Society. Non-Hodgkin Lymphoma. 2018. Accessed Feb 11 2020
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005326/en/
Contact information
Media Contacts:
Japan:
Koji Ogiwara
Daiichi Sankyo, Co., Ltd
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)
Global:
Jennifer Brennan
Daiichi Sankyo, Inc.
jbrennan2@dsi.com
+1 908 992 6631 (office)
+1 201 709 9309 (mobile)
Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GridBeyond Closes €52M Series C Funding Round to Continue Its Platform Evolution and Invest in New & Existing Markets16.4.2024 07:00:00 EEST | Press release
GridBeyond, the leading intelligent energy and smart grid platform provider for distributed energy resource management, has closed its €52M Series C financing round. The round was led by Alantra’s Energy Transition Fund, Klima. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415760197/en/ GridBeyond closes €52M Series C funding round to continue its platform evolution and invest in new & existing markets. (Graphic: Business Wire) The Series C round also included new investors Energy Impact Partners, Mirova, ABB, Constellation and Yokogawa Electric Corporation as well as investment from existing investor, Act Venture Capital. Since its foundation in 2010, GridBeyond has been developing its AI platform to help businesses unlock the full potential of energy assets, ensuring the sustainability, resilience, and affordability of energy as the world moves towards a zero-carbon future. GridBeyond’s technology unleashes the latent
World Famous Soccer Star Neymar Junior Joins Forces With Fun Brands and Enters the Cocktails and Mocktails Business With His Own Brand15.4.2024 19:00:00 EEST | Press release
Neymar da Silva Santos Júnior, known as one of the best soccer players in the world, joins forces with Fun Brands, a Miami, Florida-based beverage company, to announce a new collaborative venture of innovative, all-natural spirit- and wine-based cocktails and zero alcohol mocktails launching in Brazil later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415201897/en/ World Famous Soccer Star Neymar Junior Announces Collaborative Venture With Fun Brands to Enter Cocktail and Mocktail Business With Own Brand (Photo: Business Wire) “This is a great opportunity for me to celebrate in a new way with my fans worldwide, creating possibilities for connection beyond soccer, which is my life,” highlighted the All-star. “I want to share the flavors of Brazil that I love the most with my soccer fans at home and around the world in a different and irreverent way. The idea of also offering non-alcoholic beverages greatly att
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome15.4.2024 16:15:00 EEST | Press release
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL). CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs. In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab
Brightcove Introduces Smart TV SDKs for Roku, Samsung, and LG Devices, Empowering Media Companies to Reach New Audiences15.4.2024 16:00:00 EEST | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced the launch of its new player platforms for Roku, Samsung and LG Smart TVs. The launch of the new Software Development Kits (SDKs) has unlocked advanced features within Brightcove’s industry-leading player framework, including content protection, monetization, and analytics reporting capabilities. Designed to reduce the cost and speed of high-quality app development, media companies can more effectively target the Smart TV platforms fueling media growth while delivering a consistent, engaging premium viewer experience. “Brightcove is committed to helping media companies deliver engaging and world-class reliable streaming experiences while reducing the costs traditionally associated with launching and running an OTT service," said Scott Levine, Chief Product Officer at Brightcove. “Our comprehensive platform enables media companies to benefit from out-of-the-box functionality and deliver pre
SLB Awarded Three Completion Contracts for Petrobras’ Buzios Field15.4.2024 16:00:00 EEST | Press release
SLB (NYSE: SLB) has been awarded three contracts by Petrobras (NYSE: PBR) for completion hardware and services for up to 35 subsea wells in the development of Petrobras’ offshore Buzios Wave II oilfield. The scope of the contract includes SLB’s full bore electric interval control valves and electric subsurface safety valves. The award is a catalyst toward full production system electrification for Petrobras, improving production availability via more reliable completions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240412438623/en/ Much of the technology to be deployed in Buzios and available for other operators of Brazilian pre-salt fields was developed at SLB’s Taubaté Engineering Center in Brazil for Brazilian pre-salt, in collaboration with CENPES, the Petrobras research center, and TotalEnergies. (Photo: Business Wire) By converting to electric completions, Petrobras will gain the ability to reliably control a more s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom